Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of orelabrutinib in relapsing-remitting multiple sclerosis
CTR20211898Phase 2Active
- Sponsor
- Innovent Biologics
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib in multiple sclerosis (MS), sponsored by Innovent Biologics. Started Sep 2021; status: active.
02
Drugs
orelabrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on CTR20211898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211898.